Table 1.
Characteristics among assessed advanced or metastatic breast cancer breast cancer (A/MBC) patients treated with Eribulin (N=60)
| Characteristics | N | % |
|---|---|---|
| Age (years): Median (IQR) | 51 (41 – 59) | |
| Estrogen receptora (N=59) | ||
| Positive | 34 | 57.6 |
| Negative | 25 | 42.4 |
| Progesterone receptora (N=58) | ||
| Positive | 29 | 50.0 |
| Negative | 29 | 50.0 |
| HER2 statusa (N=59) | ||
| Negative | 37 | 62.7 |
| Positive | 22 | 37.3 |
| Triple negative breast cancer | ||
| No | 50 | 83.3 |
| Yes | 10 | 16.7 |
| Number of metastatic sites: Median (IQR) | 2 (1-3) | |
| Number of metastatic sites: | ||
| <2 sites (0 or 1) | 20 | 33.3 |
| ≥2 sites | 40 | 66.7 |
| Types of metastasis: | ||
| Non-visceral | 24 | 40.0 |
| Visceral | 27 | 45.0 |
| Both visceral and non-visceral | 9 | 15.0 |
| (Neo)adjuvant chemotherapya (N=37) | ||
| No | 8 | 21.6 |
| Yes | 29 | 78.4 |
| Eribulin used line to treat recurrent or metastatic breast cancer: Median (IQR) | 4 (3 - 6) | |
| Early-line (First and second line) | 15 | 25.0 |
| Late-line (≥ 3rd line) | 45 | 75.0 |
| Eribulin duration (days): Median (IQR) | 123 (68 – 185) | |
| Eribulin treated | ||
| As monotherapy | 46 | 76.7 |
| With Trastuzumab (±pertuzumab) | 6 | 10.0 |
| With Hormone therapy | 5 | 8.3 |
| With Othersb | 3 | 5.0 |
IQR Interquartile range, HER2 Human epidermal growth factor receptor 2, TNBC Triple negative breast cancer
athe calculation was based on those patients with available data accordingly
bothers include those were prescribed with pembrolizumab, bevacizumab, capecitabin